Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee

被引:30
作者
Lown, R. N. [1 ,2 ]
Philippe, J. [3 ]
Navarro, W. [4 ]
van Walraven, S. M. [5 ]
Philips-Johnson, L. [4 ]
Fechter, M. [5 ]
Pawson, R. [6 ]
Bengtsson, M. [7 ]
Beksac, M. [8 ]
Field, S. [9 ]
Yang, H. [10 ]
Shaw, B. E. [2 ,3 ]
机构
[1] UCL Canc Inst, Anthony Nolan Res Inst, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] OneMatch Stem Cell & Marrow Network, Ottawa, ON, Canada
[4] Natl Marrow Donor Program, Minneapolis, MN USA
[5] Europdonor Fdn, Leiden, Netherlands
[6] NHS Blood & Transplant, British Bone Marrow Registry, Watford, England
[7] Tobias Registry, Stockholm, Sweden
[8] Ankara Univ, TR-06100 Ankara, Turkey
[9] Welsh Blood Serv, Cardiff, S Glam, Wales
[10] Australian Bone Marrow Donor Registry, Sydney, NSW, Australia
关键词
COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; AUTOLOGOUS BLOOD; TRANSPLANTATION; TRANSMISSION; MOBILIZATION; COLLECTION; RECIPIENT; INFECTION; LYMPHOMA;
D O I
10.1038/bmt.2014.67
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The World Marrow Donor Association (WMDA) fosters collaboration between international registries to facilitate the exchange of hematopoietic stem cell products for unrelated stem cell donor transplantation. As indications for hematopoietic SCT grow, the movement of products across the world will increase. Although competent authorities may regulate products within their country, there is a need to protect the best interests of donors and recipients by identifying universal donor medical suitability criteria. Within this report the WMDA provides a background to unrelated adult donor and recipient safety, recommends a common framework for assessing the health of unrelated adult donors at each stage of the donation pathway and presents a novel mechanism for sharing international consensus criteria for individual medical and lifestyle conditions. Wherever possible, these criteria are evidence-based. By establishing a donor medical suitability working group, the WMDA has developed a process through which donor centers and registries may request a consensus opinion on conditions not already listed, as well as challenge existing criteria. Guidance from the WMDA is intended to complement, not supersede, guidance from national competent authorities and international regulatory bodies.
引用
收藏
页码:880 / 886
页数:7
相关论文
共 54 条
[1]   Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma [J].
Au, WY ;
Chan, EC ;
Siu, LLP ;
Lau, TCM ;
Lie, AKW ;
Ma, SK ;
Kwong, YL .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (03) :777-780
[2]   T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation [J].
Au, WY ;
Lam, CCK ;
Lie, AKW ;
Pang, A ;
Kwong, YL .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (04) :626-630
[3]   Brief report: Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation [J].
Berg, KD ;
Brinster, NK ;
Huhn, KM ;
Goggins, MG ;
Jones, RJ ;
Makary, A ;
Murphy, KM ;
Griffin, CA ;
Rosenblum-Vos, LS ;
Borowitz, MJ ;
Nousari, HC ;
Eshleman, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20) :1458-1463
[4]   B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation [J].
Bielorai, B ;
Deeg, HJ ;
Weintraub, M ;
Neumann, Y ;
Rosner, E ;
Amariglio, N ;
Rechavi, G ;
Toren, A .
BONE MARROW TRANSPLANTATION, 2003, 31 (10) :931-934
[5]   DONOR-CELL LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA [J].
BROWNE, PV ;
LAWLER, M ;
HUMPHRIES, P ;
MCCANN, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (10) :710-713
[6]   Adoptive transfer of vitiligo after allogeneic peripheral blood stem cell transplant [J].
Campbell-Fontaine, A ;
Coad, JE ;
Kovach, R ;
Ericson, SG .
BONE MARROW TRANSPLANTATION, 2005, 36 (08) :745-746
[7]   Mantle Cell Lymphoma 12 Years After Allogeneic Bone Marrow Transplantation Occurring Simultaneously in Recipient and Donor [J].
Christian, Beth ;
Zhao, Weiqiang ;
Hamadani, Mehdi ;
Sotomayor, Eduardo M. ;
Navarro, Willis .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :E629-E632
[8]   Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia [J].
Craddock, C. ;
Labopin, M. ;
Pillai, S. ;
Finke, J. ;
Bunjes, D. ;
Greinix, H. ;
Ehninger, G. ;
Steckel, N-K ;
Zander, A. R. ;
Schwerdtfeger, R. ;
Buchholz, S. ;
Kolb, H-J ;
Volin, L. ;
Fauser, A. ;
Polge, E. ;
Schmid, C. ;
Mohty, M. ;
Rocha, V. .
LEUKEMIA, 2011, 25 (05) :808-813
[9]   Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry [J].
de la Rubia, Javier ;
de Arriba, Felipe ;
Arbona, Cristina ;
Pascual, Maria J. ;
Zamora, Concha ;
Insunza, Andres ;
Martinez, Dorleta ;
Paniagua, Carmen ;
Diaz, Miguel A. ;
Sanz, Miguel A. .
HAEMATOLOGICA, 2008, 93 (05) :735-740
[10]   Brucellosis transmitted by bone marrow transplantation [J].
Ertem, M ;
Kürekçi, AE ;
Aysev, D ;
Ünal, E ;
Ikinciogullari, A .
BONE MARROW TRANSPLANTATION, 2000, 26 (02) :225-226